Antifungal compounds from microbial secondary metabolites for Fusarium control

Overview

This research program focuses on discovering novel antifungal compounds produced by antagonistic microorganisms isolated from wheat, rice, and associated soil microbiomes. The goal is to identify new lead compounds with high activity against economically important Fusarium species that cause diseases such as Fusarium head blight, bakanae disease, and crown rot. By harnessing the natural defensive chemistry of beneficial microbes, the program aims to develop new crop protection solutions that can complement or replace existing fungicides.

Technical specifications

Discovery pipeline:

• Screening of 176 previously isolated antagonistic strains using confrontation culture assays against multiple Fusarium species
• Strain identification by morphology and molecular biology, confirming genera including Streptomyces, Bacillus, and Burkholderia
• Fermentation broth production and bioactivity testing against Fusarium graminearum, Fusarium solani, Fusarium fujikuroi, Fusarium pseudograminearum, and Fusarium incarnatum

Key validated results:

• Streptomyces spp. BM2-2 produces a 14.5 mm inhibition zone against F. fujikuroi and F. pseudograminearum
• Burkholderia spp. SFbuk-1 produces a 7.3 mm inhibition zone against F. incarnatum
• Bacillus W-1 produces a 7.5 mm inhibition zone against F. graminearum and protects wheat coleoptiles from F. graminearum infection with no adverse crop effects

Planned development activities:

• In vitro and in vivo screening of secondary metabolites with broad-spectrum Fusarium inhibition
• Isolation, purification, and structural identification of active compounds
• Derivative synthesis to optimize activity
• Evaluation of systemic activity and crop safety indices

Technology readiness level

The program is at an early-to-mid discovery stage (TRL 3–4). Promising microbial strains have been identified and confirmed for antifungal activity in laboratory and initial plant protection assays. The next phase requires compound isolation, structural elucidation, and expanded in vivo validation, with an estimated three-year timeline. The team is actively seeking partners for compound isolation, purification, derivative synthesis, structure analysis instrumentation, and funding for key research personnel.